Maria Amann

6PUBLICATIONS
75CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 15, 2026
FasL-mediated death of activated intratumoral T cells drives secondary resistance to cancer immunotherapy.

|Sep 03, 2025
IL15/IL15Rα Complex Induces an Antitumor Immune Response following Radiotherapy only in the Absence of Tregs and Fails to Expand Progenitor TCF1+ CD8 T Cells.

Miles Piper, Chloe A Hodgson, Jacob Gadwa

|Sep 02, 2025
Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies.

Idil Hutter-Karakoc, Eleni Maria Varypataki, Aparna Neelakandhan

|Feb 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz

|Feb 03, 2025
IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.

Marcos Garcia-Lacarte, Sara C Grijalba, Javier Melchor

|May 21, 2024
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody.

Sara Belli, Maria Amann, Lucy Hutchinson

Pageof 1

Frequent Collaborators

3 joint publications

Christian Klein

2 joint publications

Gabriel Schnetzler

2 joint publications

Christophe Boetsch

1 joint publications

Sara Belli